References
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.
Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Baseggio L, Gazzo S, et al. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma. 2005;5(4):220–4.
Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1(8580):292–3.
Jaffe E, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–5.
Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, The JES. WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2008;117(19):5019–32.
Griesser H, Kaiser U, Augener W, Tiemann M, Lennert K. B-cell lymphoma of the mucosa-associated lymphatic tissue (MALT) presenting with bone marrow and peripheral blood involvement. Leuk Res. 1990;14(7):617–22.
Allez M, Mariette X, Linares G, Bertheau P, Jian R, Brouet JC. Low-grade MALT lymphoma mimicking Waldenstrom's macroglobulinemia. Leukemia. 1999;13(3):484–5.
Valdez R, Finn WG, Ross CW, Singleton TP, Tworek JA, Schnitzer B. Waldenstrom macroglobulinemia caused by extranodal marginal zone B-cell lymphoma: a report of six cases. Am J Clin Pathol. 2001;116(5):683–90.
Salle V, Smail A, Joly JP, Capiod JC, Gontier MF, Duhaut P, et al. Gastric MALT lymphoma presenting as Waldenstrom's macroglobulinemia without bone marrow involvement. Clin Lymphoma Myeloma. 2007;7(7):470–1.
Wohrer S, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res. 2004;10(21):7179–81.
Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(21):4643–51.
Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16(3):473–80.
Alinari L, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47(10):2096–101.
Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79(3):205–9.
Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507–13.
Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23(31):8018–24.
Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999;131(2):88–95.
Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol. 2010;16(17):2158–62.
Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16(5):1916–21.
Hitchcock S, Ng AK, Fisher DC, Silver B, Bernardo MP, Dorfman DM, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2002;52(4):1058–66.
Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21(22):4157–64.
Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005;23(28):7050–9.
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979–83.
Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13(10):2524–9.
Jager G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18):3872–7.
Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115(22):5210–7.
Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741–8.
Zucca E, Conconi A, Martinelli G, Martelli M, Thieblemont C, Johnson PW, Lopez-Guillermo A, Bouabdallah R et al. (2010) Chlorambucil plus rituximab produces better event-free survival in comparison with chlorambucil alone in the treatment of MALT Lymphoma: 5-year analysis of the 2-arms part of the IELSG-19 randomized study. In: ASH Annual Meeting Abstracts. Orange County Convention Center, Orlando, 4–7 Dec 2010 116:432
Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2011;22 (3):689–695
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, Z.J., Sandhu, G.S., Aggarwal, N. et al. IgM Monoclonal Gammopathy in Gastric MALToma. J Gastrointest Canc 45, 91–95 (2014). https://doi.org/10.1007/s12029-013-9483-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-013-9483-9